Tekturna Will Track Diovan’s Steady Growth To Blockbuster Status - Novartis
Executive Summary
Novartis is hoping sales of its new blood pressure drug Tekturna will climb steadily as morbidity and mortality data amass, eventually leading it to blockbuster status on the same trajectory as top-selling Diovan
You may also be interested in...
Tekturna’s Loss May Be Entresto’s Gain As Novartis Hopes For Change In The ATMOSPHERE
Strength of Novartis’ new heart failure drug Entresto contrasts with yet another failed outcomes study for its old renin inhibitor Tekturna.
With Its Hypertension Franchise in Crisis, Novartis Restructures
Novartis announced Jan. 13 the elimination of nearly 2,000 positions in its U.S. General Medicines business in the wake of the termination of a key clinical study of Tekturna and in anticipation of the expiration of Diovan’s U.S. patent later this year.
Efficacy Supplement Numbers On The Rise As Industry Braces For Patent Cliff
Drug makers are squeezing more new and expanded indications out of approved drugs to compensate for patent expiries and the lagging pace of new drug approvals, according to an analysis from the Tufts Center for the Study of Drug Development.